Derivatives of cephalosporin for treating cancer
AssigneesInstitut Curie, Harmonic Pharma
InventorsArnaud Sinan Karaboga, Violeta Isabel Perez-Nueno, Michel Souchet, Didier Decaudin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
Claims15
A method for treating a cancer in a subject in need thereof comprising administering to said subject an effective amount of 7-(2-amino-2-(4-hydroxyphenyl)acetamido)-8-oxo-3-(prop-1-enyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-carboxylic acid or a pharmaceutically acceptable salts thereof or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from the group consisting of breast cancer, lung cancer, and melanoma.
Dependencies are inferred from the claim text.